510(k) Report

FDA applicant

Rebound Therapeutics

Irvine, CA8 decisions2018–20232 recalls

FDA records 8 decisions for Rebound Therapeutics (Irvine, CA) from 2018 to 2023: 8 510(k) clearances. Most are in product codes GEI (Electrosurgical, Cutting & Coagulation &…) and GWG (Endoscope, Neurological). Since 2016 its 510(k)s took a median of 59 days from receipt to decision, against 146 for FDA’s reviews in the same codes and years. Its devices cite 10 predicates, 5 of them its own earlier devices. 2 recalls are linked to its devices.

FDA’s records also spell it “Rebound Therapeutics Corporation”.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, general and plastic surgery panel, where it files most

How often FDA has decided Rebound Therapeutics’s devices, and how often a recall has named them.

FDA decisions per year

1in 2023

2018: 12019: 32020: 22021: 12023: 1
2018high 3 (2019) · low 0 (2022)2026

2026 so far, outlined.

Recalls per year

1in 2025

2024: 12025: 1
2018high 1 (2024) · low 0 (2018)2026

Class I Class II/III not classified

FIG. 1 — Rebound Therapeutics by year, 2018–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Rebound Therapeutics’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report